// App-Quantinova.ai

2824 : G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors

Researchers

Presenter

  • Jessica A. Sorrentino

Principal Investigators

  • John E. Bisi

  • Patrick J. Roberts

  • Jay C. Strum

Medical Centers

  • G1 Therapeutics, Inc, Research Triangle Park, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Neutropenia

  • Solid malignancies

Biomarkers

  • Cyclin-dependent kinase 4

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Palbociclib

  • Letrozole

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved